Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
weberfr8

/by

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration

Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
weberfr8

/by

Negative impact of the IRA on patient access to innovative treatments

Negative impact of the IRA on patient access to innovative treatments
angilma1

/by

Negative impact of the IRA on patient access to innovative treatments

Negative impact of the IRA on patient access to innovative treatments
angilma1

/by

Novartis statement on Maximum Fair Price for Entresto

Novartis statement on Maximum Fair Price for Entresto
angilma1

/by

Novartis statement on Maximum Fair Price for Entresto

Novartis statement on Maximum Fair Price for Entresto
angilma1

/by

Every number has a story – my journey to Novartis as a Refugee

Every number has a story – my journey to Novartis as a Refugee
tavasat1

/by

Every number has a story – my journey to Novartis as a Refugee

Every number has a story – my journey to Novartis as a Refugee
tavasat1

/by

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by